Gaush Meditech's (HKG:2407) subsidiary Gaush Teleon obtained a class II medical device registration certificate for its self-developed intraocular lens implant system from the Guangdong Provincial Medical Products Administration, a Wednesday Hong Kong bourse filing said.
As of now, all cataract surgery therapies generally require intraocular lens implantation to treat problems like blindness due to cataracts, and high myopia, the filing said.
Gaush Teleon's intraocular lens implant system can be applied for cataract surgery and also in the implantation of phakic intraocular lenses for myopia treatment.
The ophthalmology medical business company's shares closed nearly 6% lower on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。